dc.contributor.author | Baker, LCJ | |
dc.contributor.author | Sikka, A | |
dc.contributor.author | Price, JM | |
dc.contributor.author | Boult, JKR | |
dc.contributor.author | Lepicard, EY | |
dc.contributor.author | Box, G | |
dc.contributor.author | Jamin, Y | |
dc.contributor.author | Spinks, TJ | |
dc.contributor.author | Kramer-Marek, G | |
dc.contributor.author | Leach, MO | |
dc.contributor.author | Eccles, SA | |
dc.contributor.author | Box, C | |
dc.contributor.author | Robinson, SP | |
dc.date.accessioned | 2018-08-14T10:24:23Z | |
dc.date.issued | 2018-07-23 | |
dc.identifier.citation | Frontiers in oncology, 2018, 8 pp. 271 - ? | |
dc.identifier.issn | 2234-943X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2332 | |
dc.identifier.eissn | 2234-943X | |
dc.identifier.doi | 10.3389/fonc.2018.00271 | |
dc.description.abstract | Background: Overexpression of EGFR is a negative prognostic factor in head and neck squamous cell carcinoma (HNSCC). Patients with HNSCC who respond to EGFR-targeted tyrosine kinase inhibitors (TKIs) eventually develop acquired resistance. Strategies to identify HNSCC patients likely to benefit from EGFR-targeted therapies, together with biomarkers of treatment response, would have clinical value. Methods: Functional MRI and 18F-FDG PET were used to visualize and quantify imaging biomarkers associated with drug response within size-matched EGFR TKI-resistant CAL 27 (CALR) and sensitive (CALS) HNSCC xenografts in vivo, and pathological correlates sought. Results: Intrinsic susceptibility, oxygen-enhanced and dynamic contrast-enhanced MRI revealed significantly slower baseline R2∗ , lower hyperoxia-induced ΔR2∗ and volume transfer constant Ktrans in the CALR tumors which were associated with significantly lower Hoechst 33342 uptake and greater pimonidazole-adduct formation. There was no difference in oxygen-induced ΔR1 or water diffusivity between the CALR and CALS xenografts. PET revealed significantly higher relative uptake of 18F-FDG in the CALR cohort, which was associated with significantly greater Glut-1 expression. Conclusions: CALR xenografts established from HNSCC cells resistant to EGFR TKIs are more hypoxic, poorly perfused and glycolytic than sensitive CALS tumors. MRI combined with PET can be used to non-invasively assess HNSCC response/resistance to EGFR inhibition. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 271 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | FRONTIERS MEDIA SA | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-07-02 | |
rioxxterms.versionofrecord | 10.3389/fonc.2018.00271 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Frontiers in oncology | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Pre-Clinical MRI | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radiotherapy Physics Modelling | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Pre-Clinical MRI | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radiotherapy Physics Modelling | |
pubs.publication-status | Published | |
pubs.volume | 8 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Magnetic Resonance | |
icr.researchteam | Preclinical Molecular Imaging | |
icr.researchteam | Pre-Clinical MRI | |
icr.researchteam | Radiotherapy Physics Modelling | |
dc.contributor.icrauthor | Price, Jonathan | |
dc.contributor.icrauthor | Boult, Jessica | |
dc.contributor.icrauthor | Lepicard, Elise | |
dc.contributor.icrauthor | Jamin, Yann | |
dc.contributor.icrauthor | Kramer-Marek, Gabriela | |
dc.contributor.icrauthor | Leach, Martin | |
dc.contributor.icrauthor | Box, Carol | |
dc.contributor.icrauthor | Robinson, Simon | |